Searched over 200M research papers
9 papers analyzed
These studies suggest that symptoms of low ejection fraction in heart failure patients can be improved with therapies like Baroreflex activation therapy, while early diagnosis and individualized treatment plans are crucial for managing the condition effectively.
20 papers analyzed
Low ejection fraction (EF) is a condition where the heart's left ventricle pumps out less blood than normal with each contraction. This condition is often associated with heart failure with reduced ejection fraction (HFrEF), which is characterized by an EF of 40% or less. Patients with low EF experience a range of symptoms that significantly impact their quality of life and overall prognosis.
One of the most prevalent symptoms of low EF is exercise intolerance. Patients often experience significant limitations in their ability to perform physical activities due to reduced cardiac output. This is frequently accompanied by general fatigue, making even daily tasks challenging.
Breathlessness, or dyspnea, is another common symptom. Patients with low EF often report difficulty breathing, especially during physical exertion or when lying down (orthopnea). This symptom is due to the heart's inability to pump blood efficiently, leading to fluid buildup in the lungs.
Peripheral edema, or swelling in the legs and ankles, is also a frequent symptom. This occurs because the heart's reduced pumping ability causes fluid to accumulate in the extremities.
Jugular venous distention (JVD) is a physical sign that can be observed in patients with low EF. It indicates increased pressure in the jugular vein, reflecting elevated central venous pressure due to heart failure.
Recent advancements in diagnostic tools, such as AI-enabled electrocardiograms (ECGs), have improved the early detection of low EF. These tools can identify patients with low EF more effectively, allowing for timely intervention and management.
Biomarkers like N-terminal pro-brain natriuretic peptide (NT-proBNP) are also used to assess heart failure severity. Elevated levels of NT-proBNP are indicative of heart failure and can help in diagnosing low EF. Additionally, cardiac imaging techniques, such as echocardiograms, are essential for evaluating the heart's structure and function.
Effective management of low EF often involves a combination of pharmacologic therapies. Guideline-directed medical therapies, including beta-blockers, ACE inhibitors, and diuretics, are crucial for improving symptoms and reducing hospitalizations. However, managing these medications can be challenging, especially in patients with low blood pressure.
Baroreflex activation therapy (BAT) is an emerging treatment that targets sympatho-vagal imbalance in HFrEF patients. This therapy has shown promise in improving heart failure symptoms and quality of life.
Low ejection fraction is a serious condition associated with heart failure that presents with a range of debilitating symptoms, including exercise intolerance, breathlessness, peripheral edema, and jugular venous distention. Early detection through advanced diagnostic tools and effective management with pharmacologic and device therapies are essential for improving patient outcomes. Continued research and advancements in treatment options hold promise for better managing this challenging condition.
Most relevant research papers on this topic